ArticleEndocrine connections2019
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience.
Article in Endocrine connections, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.International journal of molecular sciences · 2023Pooled it
- Therapy for aggressive pituitary tumors and carcinomas.Reviews in endocrine & metabolic disorders · 2026Review
- Aggressive and malignant pituitary tumours: does the sex matter?Pituitary · 2026Review
- Management of Recurrent and Aggressive Non-Functioning Pituitary Adenomas.Journal of clinical medicine · 2025Review
- Aggressive pituitary tumors and pituitary carcinomas: Definition, management, and overview for clinical practice.Neuro-oncology advances · 2025Article
- An 18-year Odyssey: navigating the complex path of prolactinoma management: a case report.Cardiovascular diabetology. Endocrinology reports · 2025Article
- Treatment of an Aggressive Gonadotroph Pituitary Neuroendocrine Tumor WithJCEM case reports · 2024Article
- Approach to the Patient With Prolactinoma.The Journal of clinical endocrinology and metabolism · 2023Review
- Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.The Journal of clinical endocrinology and metabolism · 2023Article
- Refractory lactotroph adenomas.Pituitary · 2023Review
- The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary.Cancers · 2023Review
- Recent Therapeutic Advances in Pituitary Carcinoma.Journal of immunotherapy and precision oncology · 2023Review
- Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.Frontiers in endocrinology · 2023Review
- Recent advances in understanding and managing pituitary adenomas.Faculty reviews · 2023Review
- Phase 1 Study of No-Carrier Added 177Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor-Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea.Cancer research and treatment · 2023Article
- Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.European journal of endocrinology · 2022Article
- Treatment of Prolactinoma.Medicina (Kaunas, Lithuania) · 2022Review
- High-risk pituitary adenomas and strategies for predicting response to treatment.Hormones (Athens, Greece) · 2022Review
- Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.European journal of endocrinology · 2022Article
- Pituitary carcinoma: reclassification and implications in the NET schema.Endocrine oncology (Bristol, England) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In aggressive pituitary tumors (PT) showing local invasion or growth/recurrence despite multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic option, while little data are available on peptide receptor radionuclide therapy (PRRT). We analyzed PRRT effectiveness, safety and long-term outcome in three patients with aggressive PT, also reviewing the current literature. Patient #1 (F, giant prolactinoma) received five cycles (total dose 37 GBq) of 111In-DTPA-octreotide over 23 months, after unsuccessful surgery and long-term dopamine-agonist treatment. Patient #2 (M, giant prolactinoma) underwent two cycles (12.6 GBq) of 177Lu-DOTATOC after multiple surgeries, radiosurgery and TMZ. In patient #3 (F, non-functioning PT), five cycles (29.8 GBq) of 177Lu-DOTATOC followed five surgeries, radiotherapy and TMZ. Eleven more cases of PRRT-treated aggressive PT emerged from literature. Patient #1 showed tumor shrinkage and visual/neurological amelioration over 8-year follow-up, while the other PTs continued to grow causing blindness and neuro-cognitive disorders (patient #2) or monolateral amaurosis (patient #3). No adverse effects were reported. Including the patients from literature, 4/13 presented tumor shrinkage and clinical/biochemical improvement after PRRT. Response did not correlate with patients' gender or age, neither with used radionuclide/peptide, but PRRT failure was significantly associated with previous TMZ treatment. Overall, adverse effects occurred only in two patients. PRRT was successful in 1/3 of patients with aggressive PT, and in 4/5 of those not previously treated with TMZ, representing a safe option after unsuccessful multimodal treatment. However, at present, considering the few data, PRRT should be considered only in an experimental setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.